Previous 10 | Next 10 |
Stemline Therapeutics (NASDAQ: STML ) -22% on preliminary Q4 revenue. More news on: Stemline Therapeutics, Inc., Avinger, Inc., DURECT Corporation, Stocks on the move, Read more ...
Stemline Therapeutics (NASDAQ: STML ) -20.4% after-hours after announcing preliminary net revenues for Q4 and the full year. More news on: Stemline Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced preliminary net revenues for 2019, as well as outlined key BP...
NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that management will present at the 38 th Annual J.P. Morgan...
The FDA Breakthrough Therapy Designation (BTD) was an offshoot of the Food and Drug Administration Safety and Innovation Act (FDASIA) that was signed on July 9, 2012 , that called for a new designation to be created. Since 2012, only 147 drugs have been approved having this designation, which...
Christmas works like glue, it keeps us all sticking together ." - Rosie Thomas Today, we profile two ' Tier 3 ' names that have been gaining momentum as 2019 comes to a close. Both should see their recently approved products have a significant sales ramp up in 2020 and thus shareholders...
Stemline Therapeutics (NASDAQ: STML ) +3% pre-market after Cantor Fitzgerald initiates coverage with an Overweight rating and $18 price target, saying Elzonris could be a "pipeline in a product" for the company and is underappreciated by investors. More news on: Stemline Therapeutics, ...
Shares of Stemline Therapeutics ( STML ) have lost a third of their value since my August article recommended buying shares given the fact that the Q2 report showed progress on multiple fronts. Recently, at the ASH (American Society of Hematology) annual meeting, the company unveiled prom...
NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, presented data from ELZONRIS ® (tagraxofusp) Phase 1/2 clinical trials ...
NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced the appointment of Robert M. Francomano as Chief Commercial O...
News, Short Squeeze, Breakout and More Instantly...
Stemline Therapeutics Inc. Company Name:
STML Stock Symbol:
NASDAQ Market:
Stemline Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / May 12, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Franklin Financial Network, Inc. (NYSE: FSB ) r...
Last week, shares of these three biotech stocks rocketed higher, but their market values are still relatively small. That has intrepid investors wondering if their recent gains could be the beginning of something much larger. Data source: Yahoo! Finance. It isn't unusual to see small-cap...
NEW YORK , May 5, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City , is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ul...